Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.7
3.4
Journals
Metabolites
Special Issues
Lipid Metabolism in Obesity and Diabetes, 2nd Edition
share announcement

Lipid Metabolism in Obesity and Diabetes, 2nd Edition

A special issue of Metabolites (ISSN 2218-1989). This special issue belongs to the section "Endocrinology and Clinical Metabolic Research".

Deadline for manuscript submissions: closed (31 October 2024) | Viewed by 3125

Special Issue Editors

Dr. Hajnalka Lőrincz

E-Mail Website
Guest Editor
Department of Internal Medicine, Faculty of Medicine, University of Debrecen, H-4032 Debrecen, Hungary
Interests: lipid metabolism; high-density lipoprotein; atherosclerosis; paraoxonase-1; adipokine; hepatokine; organokine; diabetes; obesity; insulin resistance
Special Issues, Collections and Topics in MDPI journals
Dr. Mariann Harangi

E-Mail Website
Guest Editor
Department of Internal Medicine, Faculty of Medicine, University of Debrecen, H-4032 Debrecen, Hungary
Interests: lipid metabolism; familial hypercholesterolemia; inherited dyslipidemias; atherosclerosis; non-lipid effects of lipid lowering treatment; obesity; diabetes; adipokine; hepatokine
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This Special Issue is a continuation of our previous Special Issue, “Lipid Metabolism in Obesity and Diabetes 2023”.

Obesity is characterized by an excessive accumulation of fat, which leads to a plethora of medical complications including coronary artery disease, hypertension, type 2 diabetes mellitus, insulin resistance and dyslipidemia. Furthermore, enhanced atherogenesis and premature atherosclerosis are associated with the above-mentioned diseases and cause early cardiovascular complications and increased mortality. Previously, both harmful and beneficial effects of organokines, such as adipokines, hepatokines and gut hormones, have been observed for obesity and diabetes, especially in the regulation of glucose and lipid metabolism, insulin sensitivity, inflammation, vascular senescence and endogenous oxidative stress.

Due to the success of the first volume of this Special Issue, we welcome up-to-date reviews as well as clinical and original research articles studying lipid metabolism and/or organokine disturbances in the field of obesity; moreover, we welcome papers addressing related complications such as type 2 diabetes, dyslipidemias and atherosclerosis. The non-lipid effects of lipid-lowering and antidiabetic drugs in diabetes will also be covered.

Dr. Hajnalka Lőrincz
Dr. Mariann Harangi
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Metabolites is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • lipoprotein
  • lipid metabolism
  • dyslipidemia
  • atherosclerosis
  • obesity
  • insulin resistance
  • diabetes
  • adipokine
  • hepatokine
  • oxidative stress
  • vascular senescence
  • lipid-lowering treatment
  • antidiabetic drugs

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Related Special Issue

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

11 pages, 729 KiB  
Article
Low Serum Fibroblast Growth Factor 21 Level and Its Altered Regulation by Thyroid Hormones in Patients with Hashimoto’s Thyroiditis on Levothyroxine Substitution
by Eszter Berta, Sándor Halmi, István Molnár, Dávid Hutkai, Sára Csiha, Harjit Pal Bhattoa, Hajnalka Lőrincz, Sándor Somodi, Mónika Katkó, Mariann Harangi, György Paragh, Endre V. Nagy and Miklós Bodor
Metabolites 2024, 14(10), 565; https://doi.org/10.3390/metabo14100565 - 21 Oct 2024
Viewed by 653
Abstract
Background/Objectives: Fibroblast growth factor 21 (FGF21) is a hormonal regulator of lipid and glucose metabolism exerting protection against atherosclerosis by multiple actions on the blood vessels, liver, and adipose tissues. We aimed to investigate serum FGF21 level and its relation to thyroid hormones [...] Read more.
Background/Objectives: Fibroblast growth factor 21 (FGF21) is a hormonal regulator of lipid and glucose metabolism exerting protection against atherosclerosis by multiple actions on the blood vessels, liver, and adipose tissues. We aimed to investigate serum FGF21 level and its relation to thyroid hormones and metabolic parameters among patients with Hashimoto’s thyroiditis (HT). Methods: Eighty patients with HT on levothyroxine treatment and eighty-two age- and BMI-matched adults without thyroid disease serving as controls were enrolled. Serum FGF21 concentrations were determined with an enzyme-linked immunosorbent assay. Results: Median serum FGF21 level was significantly lower in HT patients compared with controls (74.2 (33.4–148.3) pg/mL vs. 131.9 (44.8–236.3) pg/mL; p = 0.03). We found a positive correlation between FGF21 and age, triglyceride, total cholesterol, and low-density lipoprotein cholesterol in both groups, while thyroid stimulating hormone and C-reactive protein showed a positive correlation, and thyroxine had an inverse correlation with FGF21 only in control subjects. According to multiple regression analyses, thyroid status is the main predictor of FGF21 in healthy controls, while it is not a significant predictor of FGF21 among HT patients on levothyroxine supplementation therapy. Conclusions: Our results indicate that the physiological role of thyroid function in the regulation of FGF21 synthesis is impaired in HT patients, which may contribute to the metabolic alterations characteristic of HT patients. Full article
(This article belongs to the Special Issue Lipid Metabolism in Obesity and Diabetes, 2nd Edition)
►▼ Show Figures

Figure 1

Review

Jump to: Research

20 pages, 1068 KiB  
Review
Ketoacidosis and SGLT2 Inhibitors: A Narrative Review
by Carmela Morace, Giuseppe Lorello, Federica Bellone, Cristina Quartarone, Domenica Ruggeri, Annalisa Giandalia, Giuseppe Mandraffino, Letteria Minutoli, Giovanni Squadrito, Giuseppina T. Russo and Herbert Ryan Marini
Metabolites 2024, 14(5), 264; https://doi.org/10.3390/metabo14050264 - 6 May 2024
Cited by 3 | Viewed by 2066
Abstract
An acute metabolic complication of diabetes mellitus, especially type 1, is diabetic ketoacidosis (DKA), which is due to an increase in blood ketone concentrations. Sodium/glucose co-transporter-2 inhibitor (SGLT2-i) drugs have been associated with the occurrence of a particular type of DKA defined as [...] Read more.
An acute metabolic complication of diabetes mellitus, especially type 1, is diabetic ketoacidosis (DKA), which is due to an increase in blood ketone concentrations. Sodium/glucose co-transporter-2 inhibitor (SGLT2-i) drugs have been associated with the occurrence of a particular type of DKA defined as euglycemic (euDKA), characterized by glycemic levels below 300 mg/dL. A fair number of euDKA cases in SGLT2-i-treated patients have been described, especially in the last few years when there has been a significant increased use of these drugs. This form of euDKA is particularly insidious because of its latent onset, associated with unspecific symptomatology, until it evolves (progressing) to severe systemic forms. In addition, its atypical presentation can delay diagnosis and treatment. However, the risk of euDKA associated with SGLT2-i drugs remains relatively low, but it is essential to promptly diagnose and manage it to prevent its serious life-threatening complications. In this narrative review, we intended to gather current research evidence on SGLT2i-associated euDKA from randomized controlled trials and real-world evidence studies, its diagnostic criteria and precipitating factors. Full article
(This article belongs to the Special Issue Lipid Metabolism in Obesity and Diabetes, 2nd Edition)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop